Impact of squamous histology on outcomes with enfortumab vedotin in patients with advanced urothelial carcinoma: Analysis of the UNITE study.

被引：0

作者：

Jindal, Tanya

Alhalabi, Omar

Nguyen, Charles B.

Bakaloudi, Dimitra Rafailia

Nizam, Amanda

Bilen, Mehmet Asim

Basu, Arnab

Zakharia, Yousef

Milowsky, Matthew I.

Brown, Jason R.

Kilari, Deepak

Shah, Sumit

Emamekhoo, Hamid

Grivas, Petros

Hoimes, Christopher J.

Gupta, Shilpa

Bellmunt, Joaquim

Campbell, Matthew T.

Alva, Ajjai Shivaram

Koshkin, Vadim S.

机构：

[1] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Univ Texas MD Anderson Canc Ctr Houston, Dept Genitourinary Med Oncol, Houston, TX USA

[3] Michigan Med, Ann Arbor, MI USA

[4] Univ Washington, Dept Med, Div Oncol, Seattle, WA USA

[5] Cleveland Clin, Cleveland, OH USA

[6] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[7] Univ Alabama Birmingham, Birmingham, AL USA

[8] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA USA

[9] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA

[10] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[11] Med Coll Wisconsin, Dept Med, Div Hematol & Oncol, Milwaukee, WI USA

[12] Stanford Canc Ctr, Stanford, CA USA

[13] Univ Wisconsin, Madison, WI USA

[14] Univ Washington, Div Hematol & Oncol, Seattle, WA USA

[15] Fred Hutchinson Canc Ctr, Seattle, WA USA

[16] Duke Univ, Duke Canc Inst, Durham, NC USA

[17] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[18] Dana Farber Canc Inst, Boston, MA USA

[19] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[20] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI USA

[21] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

261-566-9263; 283-183-138-12099; 2; 3224; 3; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.651

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：651 / 651

页数：1

共 50 条

[11] Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer
Petrylak, Daniel P.
Chia, Yen Lin
Yu, Evan Y.
Powles, Thomas
Flaig, Thomas W.
Loriot, Yohann
O'Donnell, Peter H.
Heath, Elisabeth I.
Kojima, Takahiro
Park, Se Hoon
Sonpavde, Guru P.
Picus, Joel
Matsubara, Nobuaki
Obara, Wataru
Chudasama, Vaishali
Poondru, Srinivasu
Harrison, Michael
Kim, Eric
Brancato, Sam Joseph
Rosenberg, Jonathan E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[12] Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, Thomas
Rosenberg, Jonathan E.
Sonpavde, Guru P.
Loriot, Yohann
Duran, Ignacio
Lee, Jae-Lyun
Matsubara, Nobuaki
Vulsteke, Christof
Castellano, Daniel
Wu, Chunzhang
Campbell, Mary
Matsangou, Maria
Petrylak, Daniel P.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1125 - 1135
[13] Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study
Koshkin, Vadim S.
Henderson, Nicholas
James, Marihella
Natesan, Divya
Freeman, Dory
Nizam, Amanda
Su, Christopher T.
Khaki, Ali Raza
Osterman, Chelsea K.
Glover, Michael J.
Chiang, Ryan
Makrakis, Dimitrios
Talukder, Rafee
Lemke, Emily
Olsen, T. Anders
Jain, Jayanshu
Jang, Albert
Ali, Alicia
Jindal, Tanya
Chou, Jonathan
Friedlander, Terence W.
Hoimes, Christopher
Basu, Arnab
Zakharia, Yousef
Barata, Pedro C.
Bilen, Mehmet A.
Emamekhoo, Hamid
Davis, Nancy B.
Shah, Sumit A.
Milowsky, Matthew I.
Gupta, Shilpa
Campbell, Matthew T.
Grivas, Petros
Sonpavde, Guru P.
Kilari, Deepak
Alva, Ajjai S.
CANCER, 2022, 128 (06) : 1194 - 1205
[14] Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study
Nizam, A.
Zhang, L.
Jindal, T.
Nguyen, C. B.
Alhalabi, O.
Basu, A.
Evans, S. P.
Hoimes, C. J.
Zakharia, Y.
Milowsky, M. I.
Kilari, D.
Shah, S. A.
Davis, N. B.
Emamekhoo, H.
Gupta, S.
Bellmunt, J.
Grivas, P.
Campbell, M. T.
Alva, A.
Koshkin, V. S.
ANNALS OF ONCOLOGY, 2023, 34 : S1219 - S1219
[15] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Takahashi, Shunji
Uemura, Motohide
Kimura, Tomokazu
Kawasaki, Yoshihide
Takamoto, Atsushi
Yamaguchi, Akito
Melhem-Bertrandt, Amal
Gartner, Elaina M.
Inoue, Takashi
Akazawa, Rio
Kadokura, Takeshi
Tanikawa, Toshiki
INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1056 - 1066
[16] A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
Shunji Takahashi
Motohide Uemura
Tomokazu Kimura
Yoshihide Kawasaki
Atsushi Takamoto
Akito Yamaguchi
Amal Melhem-Bertrandt
Elaina M. Gartner
Takashi Inoue
Rio Akazawa
Takeshi Kadokura
Toshiki Tanikawa
Investigational New Drugs, 2020, 38 : 1056 - 1066
[17] Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study
Furubayashi, Nobuki
Minato, Akinori
Tomoda, Toshihisa
Masaoka, Hiroyuki
Hori, Yoshifumi
Kiyoshima, Keijiro
Negishi, Takahito
Haraguchi, Yusuke
Koga, Toshiki
Song, Yoohyun
Harada, Kenichi
ANTICANCER RESEARCH, 2024, 44 (07) : 3025 - 3032
[18] Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma
Mantia, Charlene M.
Sonpavde, Guru
EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (05) : 449 - 455
[19] Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Chang, Sam S.
JOURNAL OF UROLOGY, 2022, 207 (01): : 228 - 228
[20] Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status
Furubayashi, Nobuki
Minato, Akinori
Tomoda, Toshihisa
Masaoka, Hiroyuki
Hori, Yoshifumi
Kiyoshima, Keijiro
Negishi, Takahito
Haraguchi, Yusuke
Koga, Toshiki
Song, Yoohyun
Harada, Kenichi
Kuroiwa, Kentaro
Seki, Narihito
Fujimoto, Naohiro
Nakamura, Motonobu
ANTICANCER RESEARCH, 2024, 44 (08) : 3409 - 3417

← 1 2 3 4 5 →